author-photo

Eva-Maria Wicklein

Bayer

12

Papers

174

Citations

Citation Trend

Filter By

Papers (6) Sort By

Journal Conference Others

Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study.

2021 BMC Neurology
Show All
- Source
- Cite
- Save
Citations (0)
Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials

2019 Multiple Sclerosis Journal
Show All
- Source
- Cite
- Save
Citations (4)
The 11-year long-term follow-up study from the randomized BENEFIT CIS trial

2016 Neurology
Show All
- Source
- Cite
- Save
Citations (80)
Long-term safety of interferon beta-1b (IFNB-1b) treatment in early multiple sclerosis ( MS): The 11-year follow-up of BENEFIT (BENEFIT-11)

2016 Multiple Sclerosis Journal
Show All
- Source
- Cite
- Save
Citations (0)
Impact of early treatment of MS with interferon beta-1b: cognitive outcomes at the 11-year follow-up of BENEFIT (BENEFIT 11)

2015 Multiple Sclerosis Journal
Show All
- Source
- Cite
- Save
Citations (0)
MRI results in patients with CIS treated with interferon beta-1b: 11-year follow up in BENEFIT (BENEFIT 11)

2015 Multiple Sclerosis Journal
Show All
- Source
- Cite
- Save
Citations (0)